Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 166   

Articles published

BMY 56.48 +0.06 (0.11%)
price chart
Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher ...
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher ...
Bristol-Myers Squibb Co (NYSE:BMY): Price Reaction History  Post Registrar
Stock Update (NYSE:BMY): Bristol-Myers Squibb Co Announces EMA Validation of ...  Smarter Analyst
Analyst Ratings Worth Mentioning Today: Bristol-Myers Squibb Co (NYSE:BMY ...
Bristol-Myers Squibb Co (NYSE:BMY) remained bullish with an increase +0.88% putting the price on the $56.42 per share in last trading session ended on 9/22/2016.
IBM Retirement Fund Has $16627000 Stake in Bristol-Myers Squibb Co. (BMY)  The Cerbat Gem
Bank of America Corp (NYSE:BAC) & Bristol-Myers Squibb Co (NYSE:BMY ...  Money News
Analyst Update: Aerie Pharmaceuticals Inc, Bristol-Myers Squibb Co, and Clovis ...
Bristol-Myers Squibb Co hit an annual low of $55.02 on Monday, continuing a downward slide that begin with an early August bear gap.
Bristol-Myers Squibb Co (BMY) Could Be Due for a Bounce
The shares of drugmaker Bristol-Myers Squibb Co (NYSE:BMY) are down 1.7% at $55.82, and just hit a new annual low of $55.11, as biotechs struggle in the wake of Hillary Clinton's promise to address "excessive unjustified costs" of life-saving drugs if ...
Bristol-Myers Squibb Co (NYSE:BMY): Should It Be in Your Portfolio?  Street Report
Trending Stocks Buzzers: Bristol-Myers Squibb Co (NYSE:BMY), Synchrony ...  Post Registrar
What do Analysts Say about: Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) reported its last earnings on Oct 27 BMO (BMO = before market open, AMC= after market close).
Finally, Time To Buy Bristol-Myers  Seeking Alpha
Sadoff Investment Management LLC Reduces Stake in Bristol-Myers Squibb Co. (BMY)  BBNS
Analyst Downgrades: JPMorgan Chase & Co., Bristol-Myers Squibb Co, and Nike Inc
Analysts are weighing in on financial interest JPMorgan Chase & Co. (NYSE:JPM), drugmaker Bristol-Myers Squibb Co (NYSE:BMY), and blue-chip stock Nike Inc (NYSE:NKE).
What are analysts Suggestions on: Bristol-Myers Squibb Company (BMY)  News Oracle
Analysts: Bristol-Myers Squibb Company (NYSE:BMY) stock is worth $68.75  Review Fortune
This Crushing Blow Sent Bristol-Myers Squibb Co. Down 23% in August
Shares of Bristol-Myers Squibb (NYSE:BMY), a global drug developer focused on the development cancer, cardiovascular, and genetic-defined disease drugs, plunged 23% in the month of August according to data from S&P Global Market Intelligence.
Barclays Raises Target On Merck, Lowers Target On Bristol-Myers  Benzinga
Is Bristol-Myers Squibb Presenting an Opportunity?  GuruFocus.com
Citi Research Reevaluates Bristol-Myers, Lowers Price Target
Expectations are for an “underwhelming subgroup analysis” when the CheckMate-026 trial is presented at the forthcoming ESMO conference, Citi's Andrew Baum said in a report.
What Analysts Think about Bristol-Myers Squibb
With Opdivo and Yervoy in its portfolio, Bristol-Myers Squibb has become a leading immuno-oncology player. The company has managed to secure approximately 80 approvals for Opdivo around the world. The drug has been granted approval for about nine ...
Identifying Analyst Research Reports To Consider: Bristol-Myers Squibb Co ...  Review Fortune
Bristol-Myers Squibb Company versus Mylan NV Head to Head Compare  CML News
Price Target Analysis: Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) reported its last earnings on Jul 28 BMO (BMO = before market open, AMC= after market close).